Immune Checkpoint and Poly(ADP-Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers

TY - JOUR

T1 - Immune Checkpoint and Poly(ADP-Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers

AU - Odunsi, Kunle

AU - Pejovic, Tanja

N1 - Funding Information: reported receiving grants from the National Cancer Institute during the conduct of the study; grants from AstraZeneca and TESARO, Inc, personal fees from Merck & Co, Genentech, Immunovaccine, Inc, and Unleash Immuno Oncolytics, nonfinancial support from Truvax, Inc, and other from Tactiva Therapeutics outside the submitted work; issue and license of patent PCT/US2014025673; being a cofounder of Tactiva Therapeutics; and serving as an advisor to Immunovaccine, Inc, Unleash Immuno Oncolytics, Truvax, and Merck & Co. Dr Pejovic reported receiving personal fees from TESARO, Inc, outside the submitted work and serving as a consultant to TESARO, Inc. No other disclosures were reported.

PY - 2019/8

Y1 - 2019/8

UR - http://www.scopus.com/inward/record.url?scp=85067333115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067333115&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2019.1009

DO - 10.1001/jamaoncol.2019.1009

M3 - Editorial

C2 - 31194214

AN - SCOPUS:85067333115

SN - 2374-2437

VL - 5

SP - 1103

EP - 1105

JO - JAMA oncology

JF - JAMA oncology

IS - 8

ER -